CV Therapeutics Announces Clinical Data on Perindopril From ASCOT, EUROPA, and PREAMI to Be Presented at ESC 2005
August 30 2005 - 5:12PM
PR Newswire (US)
PALO ALTO, Calif., Aug. 30 /PRNewswire-FirstCall/ -- CV
Therapeutics, Inc. (NASDAQ:CVTX) today announced that seven
abstracts featuring data from clinical studies with perindopril,
including ASCOT, substudies from EUROPA, and PREAMI, will be
presented at the European Society of Cardiology (ESC) Congress
2005, taking place in Stockholm, Sweden from September 3 through
September 7, 2005. In addition, two abstracts featuring preclinical
studies with ranolazine have been accepted. Ranolazine --
Inhibition of Late INa by Ranolazine Improves Left Ventricular
Relaxation in a Model of Na+-Induced Ca2+ Overload. Sunday,
September 4, 2005 from 3:30 p.m. to 4:30 p.m. Central European
Summer Time (CEST). Poster Presentation #1081. -- Inhibition of
Late INa by Ranolazine Reduces Ca2+ Overload and LV Mechanical
Dysfunction in Ejecting Rat Hearts. Tuesday, September 6, 2005 from
11:45 a.m. to 12 noon CEST. Presentation # 2640. Perindopril ASCOT
-- ASCOT-BPLA: The Anglo-Scandinavian Cardiac Outcomes Trial: Blood
Pressure-Lowering Arm. Sunday, September 4, 2005 from 4:30 p.m. to
4:55 p.m. CEST. Presentation #753. PREAMI -- PREAMI: Perindopril
and Remodeling in Elderly with Acute Myocardial Infarction. Sunday,
September 4, 2005 from 11:44 a.m. to 12:01 p.m. CEST. Presentation
#128. EUROPA -- Cost-Effectiveness of Perindopril Compared to
Placebo to Prevent Cardio-Vascular Events in Stable Coronary Heart
Disease. Monday, September 5, 2005 from 3:30 p.m. to 4:30 p.m.
CEST. Poster Presentation #2297. -- Effects of Perindopril on
Long-Term Clinical Outcome of Patients with Coronary Artery Disease
and Preserved Left Ventricular Function -- The EUROPA Study.
Tuesday, September 6, 2005 from 3:30 p.m. to 4:30 p.m. CEST. Poster
Presentation #3489. -- Treatment Benefit by Perindopril in Patients
with Stable Coronary Artery Disease at Different Levels of Risk.
Wednesday, September 7, 2005 from 11:15 a.m. to 11:30 a.m. CEST.
Presentation #3663. -- Effect of Perindopril in Patients with
Stable Coronary Artery Disease: Results on Inflammatory and
Thrombosis Markers of the Pertinent Study. Wednesday, September 7,
2005 from 11:45 a.m. to 12 noon CEST. Presentation #3665. Other --
Effects of Irbesartan and Perindopril on Endothelial Function and
Inflammatory Process in Patients with Stable Angina Pectoris:
Evidence for Anti-Inflammatory Properties. Monday, September 5,
2005 from 10 a.m. to 11 a.m. CEST. Poster Presentation #1714.
Additional information regarding the European Society of Cardiology
Congress 2005 can be accessed at http://www.escardio.org/. About CV
Therapeutics CV Therapeutics, Inc., headquartered in Palo Alto,
California, is a biopharmaceutical company focused on applying
molecular cardiology to the discovery, development and
commercialization of novel, small molecule drugs for the treatment
of cardiovascular diseases. CV Therapeutics currently has three
programs in commercial or late-stage development: ACEON(R)
(perindopril erbumine) Tablets, Ranexa(TM) (ranolazine) and
regadenoson. CV Therapeutics also has other clinical and
preclinical drug development candidates and programs. The company
co-promotes ACEON(R), an ACE inhibitor with enhanced tissue
affinity, in the United States with Solvay Pharmaceuticals, Inc.
ACEON(R) is indicated for the treatment of essential hypertension
and the reduction of the risk of cardiovascular mortality or non-
fatal myocardial infarction in patients with stable coronary artery
disease. Ranexa is being developed as a novel potential treatment
for chronic angina. Regadenoson is being developed with our partner
in North America, Astellas Pharma US, Inc. for potential use as a
pharmacologic stress agent in myocardial perfusion imaging studies.
Ranexa and regadenoson have not been approved for marketing by any
regulatory authorities. Except for the historical information
contained herein, the matters set forth in this press release,
including statements as to development, clinical studies,
regulatory review, and commercialization of products, are forward-
looking statements within the meaning of the "safe harbor"
provisions of the Private Securities Litigation Reform Act of 1995.
These forward-looking statements are subject to risks and
uncertainties that may cause actual results to differ materially,
including, early stage of development; regulatory review and
approval of our products; the conduct and timing of clinical
trials; the dependence on collaborative and licensing agreements;
commercialization of products; and other risks detailed from time
to time in CV Therapeutics' SEC reports, including its Quarterly
Report on Form 10-Q for the quarter ended June 30, 2005. CV
Therapeutics disclaims any intent or obligation to update these
forward-looking statements. DATASOURCE: CV Therapeutics, Inc.
CONTACT: Investors: Christopher Chai, Vice President, Treasury and
Investor Relations, +1-650-384-8560, or Media: John Bluth, Senior
Director, Corporate Communications, +1-650-384-8850, both of CV
Therapeutics, Inc. Web site: http://www.cvt.com/
Copyright
CV Therapeutics (NASDAQ:CVTX)
Historical Stock Chart
From Jun 2024 to Jul 2024
CV Therapeutics (NASDAQ:CVTX)
Historical Stock Chart
From Jul 2023 to Jul 2024